MSB mesoblast limited
Add to My Watchlist 3.58% ! $1.62

LVAD trial was 1) a success and 2) not an MSB sponsored trial....

  1. Moreforme
    4,900 Posts.
    lightbulb Created with Sketch. 797
    clock Created with Sketch.
    22/12/19
    14:27
    Post #: 42091789
    LVAD trial was 1) a success and 2) not an MSB sponsored trial. LVAD trial is now moving into larger more advanced trials with leading US medical institutions.
    MSB Price at posting: $2.00 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 10  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Significant new gold-copper discovery at Minyari Dome delivers high-grade results
right-arrow Created with Sketch.
NEWS Diamond Drilling Expands Scale of Fiesta Copper Project After Intersecting Mineralisation
right-arrow Created with Sketch.
ACW Actinogen Confirms 100th Participant in Alzheimer’s Disease Trial and Interim Analysis Timeline
right-arrow Created with Sketch.
NEWS High-Grade Niobium Intercept Delivered by Initial Drilling at Joyce
right-arrow Created with Sketch.
NEWS Proteomics International granted first patent for endometriosis diagnostic blood test in Japan
right-arrow Created with Sketch.
NEWS Next Science to Sell Majority of Assets in Proposed Transaction
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$1.62 		Change
-0.060(3.58%) 		Mkt cap ! $2.063B
Open High Low Value Volume
$1.67 $1.68 $1.62 $8.379M 5.142M

Buyers (Bids)

No. Vol. Price($)
3 76559 $1.62
 

Sellers (Offers)

Price($) Vol. No.
$1.62 676 1
View Market Depth
Last trade - 16.10pm 03/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.